Ten Venture Leaders Life Sciences startups prepare for the Boston roadshow in November

Boston is one of the world’s major life sciences hubs and the ideal springboard for ambitious startups on their way to global expansion. For the next Venture leaders Life sciences one-week roadshow to Boston, ten startups selected from 60 applications will have the opportunity to explore the city while they forge connections for their development in the United States. They will also pitch to key US investors and meet leaders and experts from the biotech and medtech industries.

Due to the current situation, this year's selection process was conducted online. The kick-off event to celebrate the winners will be held in September at the Swiss Biotech Day 2020 and the roadshow is scheduled for November. During the extended period, Venturelab will provide support to the selected teams as they prepare for the journey in November.

The Swiss National Venture Leaders Life Sciences are:

Adiposs – is a biotech start-up company developing medical imaging products and technologies for early detection of cachexia, a fatal body wasting syndrome.

Annaida Technologies SA – has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies., enabling non-invasive chemical analysis at the scale of a single human embryo.

Araris Biotech AG – is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC)-linker technology.

Ariadne-service GmbH (ariadne.ai) – combines human and artificial intelligence to turn terabytes of histopathological microscopy data of cell cultures and neural tissue into quantitative results.

EraCal Therapeutics Ltd. – develops a novel anti-obesity drug Era-107 with superior efficacy and safety compared to the standard of care in three vertebrate species – zebrafish

KetoSwiss – developed a novel migraine preventative that improves brain energetics. Its active compound is an endogenous metabolite; a ketone body (KB), which is used by the brain as an alternative fuel to glucose, when glucose utilization or transport is limited.

LifeMatrix – develops next-generation biomimetic implants for cardiovascular indications, which have the capacity to grow and regenerate with the patient.

Neurosoft Bioelectronics – adapted semi-conductor microfabrication processes to create implantable and personalized soft implants that seamlessly interface with tissues and provide better solutions to clinicians and patients.

STIMIT – is developing a contactless stimulation device backed with a technology that can non-invasively activate the body's own breathing muscle (diaphragm) during their first days of ventilation in hospital.

Terapet – the CERN spinoff developed a monitoring device that dramatically improves the precision of proton therapy, an advanced form of radiotherapy for treating cancer.

(Press release/ran)